Table 1: Bayer AG- PharmaVitae forecasts at a glance 8
Table 2: Bayer Schering Pharma AG key product developments, Q1 2008 25
Table 3: Bayer Schering Pharma AG product deals and alliances, Q1 2008 26
Table 4: Bayer Schering Pharma AG technology deals and alliances, Q1 2008 26
Table 5: Bayer HealthCare M&A activity, Q1 2008 27
Table 6: Bayer AG company announcements, Q1 2008 28
Table 7: Bayer Schering Pharma future product milestones, Q2 2008-Q1 2010 29
Table 8: Bayer Schering Pharma product portfolio overview, sales ($m), 2001-07 43
Table 9: Bayer Schering Pharma product portfolio overview, global sales ($m), 2007-13 46
Table 10: Bayer Schering Pharma therapy portfolio overview, sales ($m), 2001-07 51
Table 11: Bayer Schering Pharma therapy portfolio overview, sales ($m), 2007-13 54
Table 12: Bayer Schering Pharma portfolio overview by geographic region, sales ($m), 2001-07 60
Table 13: Bayer Schering Pharma portfolio overview by geographic region, sales ($m), 2007-13 62
Table 14: Bayer Schering Pharma launch portfolio overview ($m), 2007-13 67
Table 15: Bayer Schering Pharma core portfolio overview ($m), 2007-13 69
Table 16: Bayer Schering Pharma expiry portfolio overview ($m), 2007-13 71
Table 17: Bayer Schering Pharma portfolio overview by molecule type ($m), 2001-07 77
Table 18: Bayer Schering Pharma product portfolio overview by molecule type ($m), 2007-13 79
Table 19: Bayer Schering Pharma product portfolio overview by source ($m), 2001-07 83
Table 20: Bayer Schering Pharma AG product portfolio overview by source ($m), 2007-13 85
Table 21: Total Bayer AG revenue by business unit ($m), 2001-07 89
Table 22: Bayer AG profit and loss account ($m), 2001-07 91
Table 23: Bayer AG balance sheet ($m), 2001-07 94
Table 24: Bayer AG operating revenue/cost analysis ($m), 2001-07 97
Table 25: Bayer AG operating cost ratio analysis (% of total revenue), 2001-07 100
Table 26: Bayer AG operating cost ratio analysis (% of total revenue), 2007-13 102
Table 27: Bayer AG operating revenue/cost analysis ($m), 2007-13 106
Table 28: Bayer AG capital employed ($m), 2001-07 109
Table 29: Bayer AG EBIT return on capital employed ($m), 2001-07 111
Table 30: Bayer AG EBIT pre-tax return/Capital employed driver analysis ($m), 2001-07 112
Table 31: Bayer AG market capitalization ($ billion), 2001-07 115
Table 32: Bayer AG total shareholder returns, 2001-07 (annual %) 117
Table 33: Bayer Schering Pharma: Key products overview 120
Table 34: Kogenate: overview 121
Table 35: Kogenate: sales forecast ($m), 2007-13 122
Table 36: Xarelto: overview 125
Table 37: Xarelto: sales forecast ($m), 2007-13 126
Table 38: Mirena: overview 128
Table 39: Mirena: sales forecast ($m), 2007-13 129
Table 40: Key players in the oral contraceptives market, 2001-13 130
Table 41: Levitra: overview 132
Table 42: Levitra: sales forecast ($m), 2007-13 133
Table 43: Yasmin: overview 135
Table 44: Yasmin: sales forecast ($m), 2007-13 136
Table 45: Key players in the oral contraceptives market, 2007-13 138
Table 46: Yaz: overview 140
Table 47: Yaz: sales forecast ($m), 2007-13 141
Table 48: Nexavar: overview 144
Table 49: Nexavar: sales forecast ($m), 2007-13 145
Table 50: Leukine: overview 148
Table 51: Leukine: sales forecast ($m), 2007-13 149
Table 52: Betaferon: overview 151
Table 53: Betaferon: sales forecast ($m), 2007-13 152
Table 54: Avelox: overview 156
Table 55: Avelox: sales forecast ($m), 2007-13 157
Table 56: Key players in the antibiotics market, 2007 158
Table 57: Ciprobay: overview 160
Table 58: Ciprobay: sales forecast ($m), 2007-13 161
Table 59: Adalat: overview 163
Table 60: Adalat: sales forecast ($m), 2007-13 164
Table 61: Glucobay: overview 167
Table 62: Glucobay: sales forecast ($m), 2007-13 168
Table 63: Bayer Schering Pharma AG's NME pipeline (Phase I-registration) 171
Table 64: Bayer Schering Pharma AG's indication broadening pipeline (Phase I-registration) 172
Table 65: Exchange rates, 2007 174
Figure 1: Bayer AG prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Bayer AG financial performance ($m), 2001-13 7
Figure 3: Bayer AG corporate development, 2001-13 9
Figure 4: Bayer Schering Pharma prescription pharmaceutical sales by source ($m), 2007-13 13
Figure 5: Bayer Schering Pharma prescription pharmaceutical sales by therapy area ($m), 2001-13 14
Figure 6: Bayer Schering Pharma SWOT analysis 16
Figure 7: Current corporate structure 32
Figure 8: M&A/divestment history Bayer AG 34
Figure 9: Bayer Schering Pharma prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 40
Figure 10: Bayer Schering Pharma key sales growth drivers and resistors ($m), 2001-07 44
Figure 11: Bayer Schering Pharma key sales growth drivers and resistors ($m), 2007-13 47
Figure 12: Bayer Schering Pharma prescription pharmaceutical sales by therapy area ($m), 2001-13 50
Figure 13: Bayer Schering Pharma prescription pharma sales by therapy area, (% of total), 2001-13 57
Figure 14: Bayer Schering Pharma prescription pharmaceutical sales by geographic region ($m), 2001-13 59
Figure 15: Bayer Schering Pharma drivers and resistors by geographic region, sales ($m), 2001-07 60
Figure 16: Bayer Schering Pharma drivers and resistors by geographic region, sales ($m), 2007-13 62
Figure 17: Bayer Schering Pharma prescription pharmaceutical sales by geographic region (% of total), 2001-13 64
Figure 18: Bayer Schering Pharma launch/core/expiry configuration ($m), 2007-13 74
Figure 19: Bayer Schering Pharma prescription pharmaceutical sales by molecule type ($m), 2001-13 76
Figure 20: Bayer Schering Pharma growth drivers & resistors by molecule type ($m), 2007-13 80
Figure 21: Bayer Schering Pharma prescription pharmaceutical sales by source ($m), 2001-13 82
Figure 22: Bayer Schering Pharma growth drivers & resistors by source ($m), 2001-07 83
Figure 23: Bayer Schering Pharma growth drivers & resistors by source ($m), 2007-13 86
Figure 24: Bayer AG operating revenue/cost analysis ($m), 2001-13 96
Figure 25: Bayer AG operating cost ratio analysis (% of total revenue), 2001-13 104
Figure 26: Bayer AG return on capital employed, EBIT margin and capital turnover, 2001-07 108
Figure 27: Return on capital employed formula 113
Figure 28: Bayer AG market capitalization ($ billion), 2001-07 116
Figure 29: Bayer AG total shareholder returns (annual %), 2001-07 117
[Tabellenverzeichnis ausblenden]
